Shoichi Ohwada

Mirogabalin for the treatment of diabetic peripheral neuropathic pain: A randomized, double‐blind, placebo‐controlled phase III study in Asian patients

Masayuki Baba, Norimitsu Matsui, Masanori Kuroha et al. · Journal of Diabetes Investigation · 2019 · 135 citations · Full text

Nursing, Pharmacology, Pharmacotherapy +17

Patritumab Deruxtecan (HER3-DXd), a Human Epidermal Growth Factor Receptor 3–Directed Antibody-Drug Conjugate, in Patients With Previously Treated Human Epidermal Growth Factor Receptor 3–Expressing Metastatic Breast Cancer: A Multicenter, Phase I/II Trial

Ian E. Krop, Norikazu Masuda, Toru Mukohara et al. · Journal of Clinical Oncology · 2023 · 122 citations · Full text

Medicine, Oncology, Pharmacology +15

Mirogabalin for the management of postherpetic neuralgia: a randomized, double-blind, placebo-controlled phase 3 study in Asian patients

Jitsu Kato, Norimitsu Matsui, Yoshihiro Kakehi et al. · Pain · 2019 · 111 citations · Full text

Nursing, Pharmacology, Pharmacotherapy +14

Results from the phase 1/2 study of patritumab deruxtecan, a HER3-directed antibody-drug conjugate (ADC), in patients with HER3-expressing metastatic breast cancer (MBC).

Ian E. Krop, Norikazu Masuda, Toru Mukohara et al. · Journal of Clinical Oncology · 2022 · 66 citations

Medicine, Oncology, Pharmacology +17

Long‐term safety and efficacy of mirogabalin in Asian patients with diabetic peripheral neuropathic pain

Masayuki Baba, Norimitsu Matsui, Masanori Kuroha et al. · Journal of Diabetes Investigation · 2019 · 50 citations · Full text

Medicine, Endocrinology, Pharmacotherapy +14